| Literature DB >> 29021787 |
Delphine Chainier1, Olivier Barraud1, Geoffrey Masson1, Elodie Couve-Deacon1, Bruno François1,2, Claude-Yves Couquet3, Marie-Cécile Ploy1.
Abstract
Objectives: Dissemination of antimicrobial resistance (AMR) is a global issue that requires the adoption of a "One-Health" approach promoting integration of human and animal health. Besides culture-dependent techniques frequently used for AMR surveillance, cultivation-independent methods can give additional insights into the diversity and reservoir of AMR genetic determinants. Integrons are molecular markers that can provide overall and reliable estimation of AMR dissemination. In this study, considering the "One-Health" approach, we have analyzed the integron digestive carriage from stools of humans and cattle living in a same area and exposed to different antibiotic selection pressures.Entities:
Keywords: One Health; antimicrobial resistance; bovine; digestive carriage; humans; integrons
Year: 2017 PMID: 29021787 PMCID: PMC5624303 DOI: 10.3389/fmicb.2017.01891
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Digestive carriage of integrons.
| Cultivation-dependent approach | Cultivation-independent approach | |||
|---|---|---|---|---|
| <0.01 | ||||
| Class 1 integrons only | 41 (21.2%) | 75 (38.7%) | <0.01 | |
| Class 2 integrons only | 2 (1.0%) | 6 (3.1%) | 0.04 | |
| Class 1 and 2 integrons | 2 (1.0%) | 4 (2.1%) | 0.41 | |
| <0.01 | ||||
| Class 1 integrons only | 63 (25.7%) | 114 (46.5%) | <0.01 | |
| Class 2 integrons only | 1 (0.4%) | 7 (2.9%) | 0.03 | |
| Class 1 and 2 integrons | 2 (0.8%) | 8 (3.3%) | 0.06 | |
| <0.01 | ||||
| Class 1 integrons only | 27 (21.1%) | 34 (26.6%) | 0.25 | |
| Class 2 integrons only | 3 (2.3%) | 11 (8.6%) | 0.03 | |
| Class 1 and 2 integrons | 1 (0.8%) | 39 (30.5%) | <0.01 |
Integron digestive carriage and antibiotic therapy with data from the cultivation-dependent approach.
| (A) | |||
|---|---|---|---|
| GP∗ ( | |||
| Integron-positive | Integron-negative | ||
| No antibiotic therapy | 43 (24.9%) | 130 (75.1%) | 0.32¤ |
| Previous or on-going antibiotic therapy | 2 (13.3%) | 13 (86.7%) | |
| Integron-positive | Integron-negative | ||
| No antibiotic therapy | 9 (25.0%) | 27 (75.0%) | 0.78# |
| Previous or on-going antibiotic therapy | 57 (27.3%) | 152 (72.7%) | |
| Integron-positive | Integron-negative | ||
| No antibiotic therapy | 77 (55.5%) | 96 (44.5%) | 0.40# |
| Previous or on-going antibiotic therapy | 5 (66.7%) | 10 (33.3%) | |
| Integron-positive | Integron-negative | ||
| No antibiotic therapy | 23 (36.1%) | 13 (63.9%) | 0.14# |
| Previous or on-going antibiotic therapy | 106 (50.7%) | 103 (49.3%) | |